| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1159/000109868 |
| P698 | PubMed publication ID | 17940348 |
| P2093 | author name string | Robert Sauermann | |
| Wolfgang Graninger | |||
| Christian Joukhadar | |||
| Markus Rothenburger | |||
| P2860 | cites work | Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers | Q24679375 |
| Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection | Q33981666 | ||
| Comparative tolerability of the HMG-CoA reductase inhibitors | Q34045770 | ||
| The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections | Q34330270 | ||
| Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus | Q34558111 | ||
| Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects | Q34882125 | ||
| In vivo pharmacodynamic activity of daptomycin | Q35005549 | ||
| Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model | Q35276965 | ||
| Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia | Q35836523 | ||
| Population pharmacokinetics of daptomycin | Q36670451 | ||
| Effect of protein binding of daptomycin on MIC and antibacterial activity | Q36757414 | ||
| In vitro synergism between daptomycin and fosfomycin against Enterococcus faecalis isolates with high-level gentamicin resistance | Q39818976 | ||
| Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs | Q40087244 | ||
| Inhibition of membrane potential-dependent amino acid transport by daptomycin | Q40088405 | ||
| In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin | Q40088863 | ||
| The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates | Q43693099 | ||
| The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species | Q44477178 | ||
| Determination of the pharmacodynamic profile of daptomycin against Streptococcus pneumoniae isolates with varying susceptibility to penicillin in a murine thigh infection model | Q44648498 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 79-91 | |
| P577 | publication date | 2007-10-16 | |
| P1433 | published in | Pharmacology | Q15759653 |
| P1476 | title | Daptomycin: a review 4 years after first approval | |
| P478 | volume | 81 |
| Q35617587 | A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics? |
| Q42115764 | A daptomycin-xylitol-loaded polymethylmethacrylate bone cement: how much xylitol should be used? |
| Q36061532 | A retrospective study of outcomes of device-associated osteomyelitis treated with daptomycin |
| Q33581795 | Activity of Fosfomycin- and Daptomycin-Containing Bone Cement on Selected Bacterial Species Being Associated with Orthopedic Infections |
| Q41902616 | An RpoB Mutation Confers Dual Heteroresistance to Daptomycin and Vancomycin in Staphylococcus aureus |
| Q34593646 | Antibiotic options for treating community-acquired MRSA. |
| Q37949641 | Bacterial meningitis: current therapy and possible future treatment options |
| Q30472227 | Biosensor applications in the field of antibiotic research--a review of recent developments |
| Q57253129 | Combined effect of non-bacteriolytic antibiotic and inhibition of matrix metalloproteinases prevents brain injury and preserves learning, memory and hearing function in experimental paediatric pneumococcal meningitis |
| Q91803575 | Combining Ceftriaxone with Doxycycline and Daptomycin Reduces Mortality, Neuroinflammation, Brain Damage, and Hearing Loss in Infant Rat Pneumococcal Meningitis |
| Q38086339 | Current use of daptomycin in cardiac surgery and postoperative intensive care |
| Q42743421 | Daptomycin for the treatment of Gram-positive microorganisms in the critically-ill patient |
| Q44738071 | Daptomycin for the treatment of gram-positive infections after cardiac surgery |
| Q42393393 | Daptomycin susceptibility of methicillin resistant Staphylococcus aureus (MRSA). |
| Q37762644 | Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machinery |
| Q40982610 | Daptomycin, a last-resort antibiotic, binds ribosomal protein S19 in humans. |
| Q55518748 | Daptomycin: a comparison of two intravenous formulations. |
| Q85228202 | Determination of daptomycin in human plasma by liquid chromatography-tandem mass spectrometry. Clinical application |
| Q78446165 | Dolyemycins A and B, two novel cyclopeptides isolated from Streptomyces griseus subsp. griseus HYS31 |
| Q42210111 | Dosing strategy to allow continued therapy with daptomycin after asymptomatic increases in creatine kinase levels |
| Q38007737 | Drug induced rhabdomyolysis |
| Q42577905 | Effects of azithromycin in combination with vancomycin, daptomycin, fosfomycin, tigecycline, and ceftriaxone on Staphylococcus epidermidis biofilms |
| Q24656785 | Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae |
| Q53686599 | Failure of daptomycin to kill Staphylococcus aureus: impact of bacterial membrane fatty acid composition. |
| Q33431190 | Identification of a new antimicrobial lysine-rich cyclolipopeptide family from Xenorhabdus nematophila |
| Q53070940 | Individualising Therapy to Minimize Bacterial Multidrug Resistance. |
| Q37800939 | Invasive community-associated MRSA infections: epidemiology and antimicrobial management |
| Q58795935 | Mechanism of High-Level Daptomycin Resistance in |
| Q92703232 | More Than a Pore: A Current Perspective on the In Vivo Mode of Action of the Lipopeptide Antibiotic Daptomycin |
| Q36657841 | Multidrug-resistant organisms in military wounds from Iraq and Afghanistan |
| Q39135986 | Neuropsychiatric Effects of Antimicrobial Agents |
| Q36888137 | Pharmacokinetic Variability of Daptomycin during Prolonged Therapy for Bone and Joint Infections |
| Q37284356 | Pre-clinical experience with daptomycin |
| Q34308017 | Preclinical advantages of intramuscularly administered peptide A3-APO over existing therapies in Acinetobacter baumannii wound infections |
| Q38282693 | Reduction in membrane phosphatidylglycerol content leads to daptomycin resistance in Bacillus subtilis |
| Q46286205 | Role of DptE and DptF in the lipidation reaction of daptomycin |
| Q44899027 | Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy. |
| Q33429168 | Safety profiles of old and new antimicrobials for the treatment of MRSA infections. |
| Q37875765 | Short native antimicrobial peptides and engineered ultrashort lipopeptides: similarities and differences in cell specificities and modes of action |
| Q92481072 | Stability of daptomycin reconstituted vials and infusion solutions |
| Q40764649 | Study on daptomycin use and implementation of an antimicrobial stewardship program |
| Q35806369 | Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus |
| Q41034745 | Systemic antimicrobial therapy in osteomyelitis |
| Q38191612 | The Interplay between Daptomycin and the Immune System |
| Q92702287 | The calcium-dependent lipopeptide antibiotics: structure, mechanism, & medicinal chemistry |
| Q37373526 | The structural diversity of acidic lipopeptide antibiotics |
| Q37853179 | Treatment of prosthetic osteoarticular infections. |
Search more.